# Revotar Biopharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revotar-biopharmaceuticals

- Industry: Biotechnology
- Headquarters: Hennigsdorf, Germany
- Website: www.revotar.de
- Total disclosed funding: $15M
- Latest round: Series A (Sep 23, 2008)
- Investors on record: 4

## About

Revotar Biopharmaceuticals AG is a Germany-based biopharmaceutical company focused on developing innovative therapeutic solutions targeting serious medical conditions. Their work integrates advanced technologies to enhance treatment efficacy and improve patient outcomes.Revotar Biopharmaceuticals AG operates in Hennigsdorf, Germany, and specializes in biopharmaceutical development. The company received notable funding in February 2012, when they raised EUR 2.50 mn through a GRANT from the German Federal State of Brandenburg, totaling EUR 5.30 mn raised overall. The company has successfully completed 7 deals to date.Revotar specializes in innovative technology solutions aimed at enhancing user experience and operational efficiency. Their core product offerings include a suite of software applications designed for data analytics and process automation, which cater to businesses seeking to streamline their operations. These applications are particularly beneficial for industries requiring robust data management and insightful analytics, such as finance, healthcare, and logistics. The company’s products have been released over the past few years, with a focus on continuous improvement and integration of the latest technological advancements. Revotar serves a diverse clientele that includes mid-sized enterprises and large corporations across various geographical markets, notably in Western Europe and North America, where the demand for advanced technological solutions is rapidly growing.Revotar's revenue model is structured around B2B transactions, primarily through subscription-based services and partnerships with key industry players. Clients typically engage with the firm through annual subscriptions that provide access to their suite of software solutions, ensuring continuous support and updates. The pricing plans are designed to accommodate a range of business sizes, with tailored packages that allow companies to select features that best meet their operational needs. Flagship products within their portfolio are instrumental in driving revenue, as they provide significant value to clients aiming to leverage data for strategic decision-making. The company also explores collaborative arrangements with retailers to enhance their market reach and drive additional sales through direct partnerships.Revotar Biopharmaceuticals AG is focusing on designing and launching new products aimed at enhancing their therapeutic solutions, although specific release dates have not been disclosed. The company plans to expand its operations into new markets, particularly targeting regions in Eastern Europe and North America by 2025. Recent funding will support these growth initiatives and the development of new technology to improve patient care and treatment options.

## Funding rounds

- Series A, Sep 23, 2008, $7.5M — BMP, Brandenburg Kapital
- Series A, Sep 22, 2008, $7.5M — BMP, Deutsche Venture Capital, MVC

## Investors

- BMP (https://capitalatlas.ai/funds/bmp) — Series A
- Deutsche Venture Capital (https://capitalatlas.ai/funds/deutsche-venture-capital) — Series A
- MVC (https://capitalatlas.ai/funds/mvc) — Series A
- Brandenburg Kapital (https://capitalatlas.ai/funds/brandenburg-kapital) — Series A